text: <unk>  is a three-drug combination of<unk>  (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and<unk>  (FTC) and<unk><unk>  (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs) that is FDA approved for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of<unk> <unk> <unk><unk> . There is a Black Box Warning for this drug as shown here.  Common adverse reactions include diarrhea, nausea, and headache..
option_0: Bictegravir / emtricitabine / tenofovir alafenamide
option_1: Dolutegravir / rilpivirine
option_2: Sofosbuvir / velpatasvir
option_3: Ledipasvir / sofosbuvir
option_4: Elbasvir / grazoprevir
option_5: Lopinavir ritonavir
option_6: Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate
option_7: Ombitasvir / paritaprevir / ritonavir / dasabuvir